Allorion Therapeutics

Executive Summary

Allorion Therapeutics is a US-China biotech company leveraging an integrated platform combining allosteric inhibitor discovery, targeted protein degradation, and other modalities to develop novel small-molecule drugs for oncology and immunology. Founded in 2020 and headquartered in Cambridge, MA, the company has raised $50 million to build a preclinical pipeline aimed at overcoming drug resistance and improving patient outcomes. Allorion's approach targets undruggable proteins and resistance mechanisms in cancer and immune disorders, positioning it as a potential leader in next-generation small-molecule therapies. With a strong scientific team and proprietary platform, the company is advancing multiple programs toward clinical development, though it remains at a preclinical stage without disclosed lead candidates.

Upcoming Catalysts (preview)

• Q1 2027IND submission for lead oncology program40% success
• Q3 2026Series B funding round60% success
• Q2 2026Presentation of preclinical data at major conference (e.g., AACR)75% success